Phathom Pharmaceuticals, Inc. (PHAT) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Florham Park, NJ, アメリカ. 現CEOは Steven L. Basta.
PHAT を有する IPO日 2019-10-25, 427 名の正社員, に上場 NASDAQ Global Select, 時価総額 $998.38M.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
